These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36196576)

  • 1. Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis.
    Pietras EM; DeGregori J
    Cancer Discov; 2022 Oct; 12(10):2234-2236. PubMed ID: 36196576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced PU.1 Expression Collaborates with Tet2 Loss to Trigger Myeloid Leukemogenesis.
    Schleicher WE; Pietras EM
    Blood Cancer Discov; 2022 Sep; 3(5):378-381. PubMed ID: 36065607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
    Shimoda K; Shide K; Kameda T; Hidaka T; Kubuki Y; Kamiunten A; Sekine M; Akizuki K; Shimoda H; Yamaji T; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A
    J Clin Exp Hematop; 2015; 55(3):145-9. PubMed ID: 26763362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of TET2 mutations in myeloid and lymphoid neoplasms].
    Chiba S
    Rinsho Ketsueki; 2016 Jun; 57(6):715-22. PubMed ID: 27384850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid.
    Cai Z; Lu X; Zhang C; Nelanuthala S; Aguilera F; Hadley A; Ramdas B; Fang F; Nephew K; Kotzin JJ; Williams A; Henao-Mejia J; Haneline L; Kapur R
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33090974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 deficiency promotes MDS-associated leukemogenesis.
    Huang F; Sun J; Chen W; Zhang L; He X; Dong H; Wu Y; Wang H; Li Z; Ball B; Khaled S; Marcucci G; Li L
    Blood Cancer J; 2022 Oct; 12(10):141. PubMed ID: 36195586
    [No Abstract]   [Full Text] [Related]  

  • 10. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
    Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage migration inhibitory factor is overproduced through EGR1 in TET2
    Pronier E; Imanci A; Selimoglu-Buet D; Badaoui B; Itzykson R; Roger T; Jego C; Naimo A; Francillette M; Breckler M; Wagner-Ballon O; Figueroa ME; Aglave M; Gautheret D; Porteu F; Bernard OA; Vainchenker W; Delhommeau F; Solary E; Droin NM
    Commun Biol; 2022 Feb; 5(1):110. PubMed ID: 35115654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
    Roche-Lestienne C; Marceau A; Labis E; Nibourel O; Coiteux V; Guilhot J; Legros L; Nicolini F; Rousselot P; Gardembas M; Helevaut N; Frimat C; Mahon FX; Guilhot F; Preudhomme C;
    Leukemia; 2011 Oct; 25(10):1661-4. PubMed ID: 21637286
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
    Pronier E; Almire C; Mokrani H; Vasanthakumar A; Simon A; da Costa Reis Monte Mor B; Massé A; Le Couédic JP; Pendino F; Carbonne B; Larghero J; Ravanat JL; Casadevall N; Bernard OA; Droin N; Solary E; Godley LA; Vainchenker W; Plo I; Delhommeau F
    Blood; 2011 Sep; 118(9):2551-5. PubMed ID: 21734233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
    Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
    Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
    Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
    Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demethylation of the RB1 promoter concomitant with reactivation of TET2 and TET3 impairs gastric carcinogenesis in K19-Wnt1/C2mE transgenic mice.
    Cao D; Jia Z; Wu Y; Su T; Zhao D; Wu M; Tsukamoto T; Oshima M; Jiang J; Cao X
    Life Sci; 2020 Dec; 263():118580. PubMed ID: 33058920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of TET2 and TET3 in regulatory T cells unleashes effector function.
    Yue X; Lio CJ; Samaniego-Castruita D; Li X; Rao A
    Nat Commun; 2019 May; 10(1):2011. PubMed ID: 31043609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.